Experimental MS drug trial halted early – only 8 patients enrolled
NCT ID NCT04625153
First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tested a new protein injection called RC18 in people with relapsing-remitting multiple sclerosis (MS). The goal was to see if it is safe and can reduce relapses. Only 8 people took part before the study was stopped early. The results will help design future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Third Affiliated Hospital,Sun Yat-Sen University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.